These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 38254784)

  • 1. It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.
    Zaalberg A; Pottendorfer E; Zwart W; Bergman AM
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in prostate cancer: clinical implications.
    Conteduca V; Hess J; Yamada Y; Ku SY; Beltran H
    Transl Androl Urol; 2021 Jul; 10(7):3104-3116. PubMed ID: 34430414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.
    Singh VK; Kainat KM; Sharma PK
    Vitam Horm; 2023; 122():253-282. PubMed ID: 36863797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.
    Kumar Mamidi TK; Wu J; Hicks C
    Biomed Res Int; 2021; 2021():6641429. PubMed ID: 33511206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity in prostate cancer and the role of targeted therapy.
    Khan S; Baligar P; Tandon C; Nayyar J; Tandon S
    Life Sci; 2024 Jan; 336():122270. PubMed ID: 37979833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
    Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
    Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to targeting epigenetic regulation in prostate cancer.
    Thompson D; Choo N; Bolton DM; Lawrentschuk N; Risbridger GP; Lawrence MG; Taylor RA
    Curr Opin Urol; 2022 Sep; 32(5):472-480. PubMed ID: 35869742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer.
    Roy P; Singh KP
    Int Rev Cell Mol Biol; 2023; 380():173-210. PubMed ID: 37657858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.
    Sarvari P; Sarvari P; Ramírez-Díaz I; Mahjoubi F; Rubio K
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiota and the landscape of the prostate tumor microenvironment.
    Gupta KR; Kyprianou N
    Am J Clin Exp Urol; 2023; 11(5):352-360. PubMed ID: 37941651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer.
    Lin M; Sun X; Lv L
    Mol Ther Oncolytics; 2023 Jun; 29():91-106. PubMed ID: 37215386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cancer epigenome: Non-cell autonomous player in tumor immunity.
    Kato S; Maeda Y; Sugiyama D; Watanabe K; Nishikawa H; Hinohara K
    Cancer Sci; 2023 Mar; 114(3):730-740. PubMed ID: 36468774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.
    Gkountakos A; Delfino P; Lawlor RT; Scarpa A; Corbo V; Bria E
    Ther Adv Med Oncol; 2021; 13():17588359211006947. PubMed ID: 34104224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.
    Niu Y; Chen J; Qiao Y
    Front Immunol; 2022; 13():836223. PubMed ID: 35140725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant DNA methylation and prostate cancer.
    Majumdar S; Buckles E; Estrada J; Koochekpour S
    Curr Genomics; 2011 Nov; 12(7):486-505. PubMed ID: 22547956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
    Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
    Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
    Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment pH-responsive pentagonal gold prism-based nanoplatform for multimodal imaging and combined therapy of castration-resistant prostate cancer.
    Tan H; Liu Y; Hou N; Cui S; Liu B; Fan S; Yu G; Han C; Zheng D; Li W; Liu Y; Xu B; Wang Z; Cui D
    Acta Biomater; 2022 Mar; 141():408-417. PubMed ID: 35032718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.